Illumina (ILMN)
NASDAQ: ILMN · Diagnostics & Research · San Diego, CA
Our rating: Neutral
Neutral reaffirmed at $226.58, moderate conviction, November 2, 2026.
Breaks if: The call turns Positive if revenue growth returns to +5% or above for two consecutive quarterly prints within the next 12 months, signaling the genomics cycle has genuinely re-accelerated. It turns Cautious if revenue declines worsen to -5% or more year-over-year for two consecutive quarters, or if FCF margin slides below 15% in any single quarter.
Key figures
| Market value | $29.2B |
|---|---|
| Revenue, last 12 months | $4.5B |
| Net income, last 12 months | $895M |
| Free cash flow, last 12 months | $1.1B |
| Price to earnings | 32.6× |
| Free cash flow yield | 3.6% |
| Dividend yield | 0.0% |
| Operating margin | 21.2% |
| Return on equity | 32.4% |
| Beta to the S&P 500 | 1.10 |
| Volatility, annualized | 47.6% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 27, 2026 | $1.1B | 4.2% | $1.43 | $379M |
| June 28, 2026 | $1.2B | 9.4% | $1.35 | $161M |
| March 29, 2026 | $1.1B | 4.8% | $0.87 | $251M |
| December 28, 2025 | $1.2B | 5.0% | $2.16 | $266M |
| September 28, 2025 | $1.1B | 0.4% | $0.98 | $253M |
| June 29, 2025 | $1.1B | −4.8% | $1.49 | $204M |
| March 30, 2025 | $1.0B | −3.3% | $0.82 | $208M |
| December 29, 2024 | $1.1B | −1.6% | $1.17 | $335M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $1.23B: Claude 42%, Gemini 65%, Mistral 52%
- Diluted earnings per share are at least $2.16: Claude 35%, Gemini 20%, Mistral 22%
- Free cash flow for the quarter is at least $0.27B: Claude 52%, Gemini 80%, Mistral 62%
- Backlog at the end of the quarter is at least $0.93B: Claude 38%, Gemini 35%, Mistral 45%
22 ledger entries and 48 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.